Payment overview · 2025
General Payments
$13.52
1 reported records · 1 companies
Healthcare provider profile · identity verified
Sheri Davis Lim, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HIGH POINT, NC · NPI 1881628121
Verified facts
What the public records show
CMS Open Payments records show Sheri Davis Lim, DO received $13.52 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.52 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.52 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 131 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 340 | 97 |
| Gabapentin | Gabapentin | 283 | 78 |
| Lisinopril | Lisinopril | 278 | 84 |
| Omeprazole | Omeprazole | 269 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 255 | 73 |
| Losartan Potassium | Losartan Potassium | 229 | 81 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 219 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 55 |
| Alprazolam | Alprazolam | 192 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 66 |
| Metformin Hcl | Metformin Hcl | 186 | 62 |
| Furosemide | Furosemide | 185 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 60 |
| Tramadol Hcl | Tramadol Hcl | 155 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 49 |
| Potassium Chloride | Potassium Chloride | 138 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 38 |
| Carvedilol | Carvedilol | 128 | 36 |
| Pregabalin | Pregabalin | 122 | 31 |
| Ozempic | Semaglutide | 119 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 23 |
| Clonazepam | Clonazepam | 115 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 113 | 18 |
| Sertraline Hcl | Sertraline Hcl | 113 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 28 |
| Eliquis | Apixaban | 97 | 21 |
| Glipizide | Glipizide | 97 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 30 |
| Lorazepam | Lorazepam | 93 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 27 |
| Trazodone Hcl | Trazodone Hcl | 86 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 15 |
| Meloxicam | Meloxicam | 81 | 29 |
| Montelukast Sodium | Montelukast Sodium | 77 | 24 |
| Mounjaro | Tirzepatide | 77 | 16 |
| Ibuprofen | Ibuprofen | 71 | 19 |
| Celecoxib | Celecoxib | 69 | 25 |
| Mirtazapine | Mirtazapine | 68 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 68 | 17 |
| Jardiance | Empagliflozin | 65 | 20 |
| Simvastatin | Simvastatin | 64 | 21 |
| Myrbetriq | Mirabegron | 62 | 14 |
| Baclofen | Baclofen | 60 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 20 |
| Januvia | Sitagliptin Phosphate | 54 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 13 |
| Ezetimibe | Ezetimibe | 52 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 20 |
| Bupropion Xl | Bupropion Hcl | 50 | 16 |
| Famotidine | Famotidine | 50 | 16 |
| Azithromycin | Azithromycin | 49 | 43 |
| Buspirone Hcl | Buspirone Hcl | 49 | 18 |
| Alendronate Sodium | Alendronate Sodium | 46 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Fluconazole | Fluconazole | 45 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 13 |
| Meclizine Hcl | Meclizine Hcl | 42 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 15 |
| Colchicine | Colchicine | 39 | 12 |
| Donepezil Hcl | Donepezil Hcl | 39 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 28 |
| Promethazine Hcl | Promethazine Hcl | 39 | suppressed |
| Telmisartan | Telmisartan | 38 | 11 |
| Valacyclovir | Valacyclovir Hcl | 38 | 14 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Estradiol | Estradiol | 37 | 12 |
| Methylprednisolone | Methylprednisolone | 37 | 30 |
| Farxiga | Dapagliflozin Propanediol | 35 | 12 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Prednisone | Prednisone | 33 | 29 |
| Glipizide Er | Glipizide | 32 | 14 |
| Cephalexin | Cephalexin | 31 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | 12 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 15 |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 18 |
| Linzess | Linaclotide | 25 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 19 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 16 |
| Topiramate | Topiramate | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Abilify Maintena | Aripiprazole | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.52 · 1 records | AstraZeneca Pharmaceuticals LP | FARXIGA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error